Core Laboratories Inc.
CLB
$13.32
$0.141.06%
NYSE
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -11.90% | 2.78% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -11.90% | 2.78% | |||
| Cost of Revenue | -6.80% | 4.40% | |||
| Gross Profit | -31.37% | -2.97% | |||
| SG&A Expenses | 39.24% | -0.55% | |||
| Depreciation & Amortization | 2.62% | 2.06% | |||
| Other Operating Expenses | -6.15% | 4.53% | |||
| Total Operating Expenses | -2.70% | 3.92% | |||
| Operating Income | -86.95% | -5.71% | |||
| Income Before Tax | -107.59% | -27.66% | |||
| Income Tax Expenses | -103.10% | 115.61% | |||
| Earnings from Continuing Operations | -114.68% | -64.69% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 80.11% | 36.49% | |||
| Net Income | -115.95% | -65.25% | |||
| EBIT | -86.95% | -5.71% | |||
| EBITDA | -69.45% | -4.29% | |||
| EPS Basic | -116.13% | -65.56% | |||
| Normalized Basic EPS | -112.09% | -3.47% | |||
| EPS Diluted | -116.13% | -64.67% | |||
| Normalized Diluted EPS | -112.09% | -1.77% | |||
| Average Basic Shares Outstanding | -1.34% | 0.94% | |||
| Average Diluted Shares Outstanding | -1.34% | -0.81% | |||
| Dividend Per Share | -- | 0.00% | |||
| Payout Ratio | -7.19% | 1.88% | |||